BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q4 2025 Earnings Call Transcript February 26, 2026
BioCryst Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $1.12, expectations were $0.07.
Operator: Good day, and welcome to the BioCryst Fourth Quarter 2025 Conference Call. [Operator Instructions] Please note this event is being recorded. I would now like to turn the conference over to Nick Wilder with BioCryst. Please go ahead.
Nick Wilder: Good morning, and welcome to...
